Cargando…
RNF8–CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and exhibits an overall poor outcome. Due to the lack of targeted therapy, conventional systemic chemotherapy has been the main strategy for the treatment of TNBC. Further evidence has shown that combining radiation wi...
Autores principales: | Kao, Chieh-Ni, Moi, Sin-Hua, Hou, Ming-Feng, Luo, Chi-Wen, Chen, Fang-Ming, Pan, Mei-Ren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8307233/ https://www.ncbi.nlm.nih.gov/pubmed/34357122 http://dx.doi.org/10.3390/jpm11070655 |
Ejemplares similares
-
Correction: Kao et al. RNF8–CDH1 Co-Expression Predicts Clinical Benefit of Chemoradiotherapy in Triple-Negative Breast Cancer. J. Pers. Med. 2021, 11, 655
por: Kao, Chieh-Ni, et al.
Publicado: (2022) -
Chromatin Remodeling Enzyme Cluster Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Breast Cancer
por: Kuo, Chia-Yu, et al.
Publicado: (2023) -
RNF181 modulates Hippo signaling and triple negative breast cancer progression
por: Zhou, Rui, et al.
Publicado: (2020) -
FAK is Required for Tumor Metastasis-Related Fluid Microenvironment in Triple-Negative Breast Cancer
por: Pan, Mei-Ren, et al.
Publicado: (2019) -
The ubiquitin ligase RNF8 regulates Rho GTPases and promotes cytoskeletal changes and motility in triple‐negative breast cancer cells
por: Pereira De Carvalho, Bruno, et al.
Publicado: (2020)